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Available online 5 April 2017Background: Contrast-induced acute kidney injury (CI-AKI) is a recognised complication during primary PCI that
affects short and long term prognosis. The aim of this study was to assess the impact of point-of-care (POC) pre-
PPCI creatinine and eGFR testing in STEMI patients.
Methods: 160 STEMI patients (STATCREAT group)with pre-procedure POC testing of Cr and eGFRwere compared
with 294 consecutive retrospective STEMI patients (control group). Patients were further divided into subjects
with or without pre-existing CKD.
Results: The incidence of CI-AKI in the whole population was 14.5% and not different between the two overall
groups. For patients with pre-procedure CKD, contrast dose was signiﬁcantly reduced in the STATCREAT group
(124.6 ml vs. 152.3 ml, p=0.015). The incidence of CI-AKI was 5.9% (n=2) in the STATCREAT group compared
with 17.9% (n= 10) in the control group (p= 0.12). There was no difference in the number of lesions treated
(1.118 vs. 1.196, p= 0.643) or stents used (1.176 vs. 1.250, p= 0.78). For non-CKD patients, there was no sig-
niﬁcant difference in contrast dose (172.4 ml vs. 158.4 ml, p = 0.067), CI-AKI incidence (16.7% vs. 13.4%, p =
0.4), treated lesions (1.167 vs. 1.164, p=1.0) or stents used (1.214 vs. 1.168, p=0.611) between the two groups.
Conclusions: Pre-PPCI point-of-care renal function testing did not reduce the incidence of CI-AKI in the overall
group of STEMI patients. In patients with CKD, contrast dosewas signiﬁcantly reduced, but a numerical reduction
in CI-AKIwas not found to be statistically signiﬁcant. No signiﬁcant differenceswere found in the non-CKDgroup.






Contrast induced acute kidney injury (CI-AKI) is a recognised compli-
cation of coronary angiography and percutaneous coronary interven-
tions (PCI) [1]. Although its incidence in low-risk patients undergoing
elective procedures is b3.5% [2], it dramatically increases to 16% to 19%
in ST-elevation myocardial infarction (STEMI) patients undergoing pri-
mary PCI (PPCI) [3,4]. Left ventricular systolic dysfunction and systemic
hypotension in the context of STEMI, along with difﬁculties inability and freedom from bias of
Centre, Basildon and Thurrock
ayne, Essex SS16 5NL, United
e).
land Ltd. This is an open access articlimplementation of renal prophylactic measures before exposure to con-
trast media probably explain the increased incidence compared to stable
patients [5,6]. Its development is not a benign condition but is associated
with increased short-term and long-term morbidity and mortality,
prolonged hospitalisation, and long-term renal impairment [7,8,9]. In pa-
tientswith STEMI undergoing PPCI, correlationwith adverse prognosis is
even stronger [4,10]. Several risk factors for CI-AKI have been identiﬁed
such as old age, chronic kidney disease (CKD), diabetes mellitus, anae-
mia, impaired left ventricular systolic function, hemodynamic instability
and contrast media volume used [11]. Its pathogenesis is not completely
understood, but there is evidence that CI-AKI occurs as a combination of
oxidative stress, ischemic injury, direct toxicity, and obstruction of the
renal tubular epithelium [12]. Based on this knowledge multiple strate-
gies for CI-AKI risk reduction have been tested in clinical studies: various
hydration protocols, ministration of N-acetylcysteine, use of ascorbic
acid, different contrast agents, haemoﬁltration protocols and statine under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ﬂicting. Hydration with normal saline starting 12 h pre and continuing
up to 24 h post procedure is the only recommended intervention for pre-
vention of CI-AKI in the recent ESC/EACS guidelines on myocardial
revascularisation, while pre-treatment (starting 12–48 h pre-
procedure)with high dose statins should be considered [20]. It is obvious
that none of these pre-planned interventions can be implemented in the
acute setting of PPCI, making prevention of CI-AKI in STEMI patients a
challenge. Alternative ways of preventing CI-AKI in this particular popu-
lation are needed.
Over the last few years there has been miniaturisation of devices
measuring biochemical parameters and now creatinine and estimated
glomerular ﬁltration rate (eGFR) can be estimated rapidly at point-of-
care with a near patient device [21]. The aim of this study was to assess
the impact of point-of-care pre-procedure creatinine and eGFR mea-
surements with immediate feedback to the operator on patients pre-
senting with ST segment elevation myocardial infarction undergoing
primary PCI.
2. Methods
2.1. Study design and population
This is a pre and post interventional study comparing two cohorts of
STEMI patients who underwent primary PCI in a high volume tertiary
centre. In the intervention group, point of care pre-primary PCI creati-
nine and eGFR were measured with the results available instantly and
feedback to the operator (STATCREAT group). This groupwas then com-
pared with a retrospective group used as control (Control group). We
expected a beneﬁt from point-of-care testing in patients with pre-PCI
renal dysfunction, so for the purpose of the analysis patients were fur-
ther divided into subjects with or without pre-existing CKD.
2.2. STATCREAT group
Patients presenting with chest pain for N30 min and ST elevation
≥2 mm in ≥2 contiguous chest leads or ≥1 mm in ≥2 contiguous limb
leads or new left bundle branch block (LBBB) due to undergo primary
PCI were enrolled. Recruitment took place in a period of 5 months
(March to August 2014) depending on availability of point-of-care test-
ing. Patients with cardiogenic shockwere excluded. Routine blood sam-
ples were taken at the time of sheath insertion as per hospital protocol.
Creatinine and eGFR were tested using the Nova Biomedical STAT SEN-
SOR (MA, USA). The amount of blood required with this device is 1.2 μl,
while processing time is 30 s. The operator was informed of the result
and continued with the procedure. Patients in whom angiography
showed no signiﬁcant atherosclerotic lesions or were referred for emer-
gency coronary artery bypass grafting (CABG) were excluded from the
analysis. PCI was performed according to international guidelines. Radi-
al access was used as the default approach. Patients were loaded with
300 mg aspirin and 600 mg clopidogrel or 60 mg Prasugrel or 180 mg
Ticagrelor. They received a bolus of 70–100 IU/kg of unfractionated hep-
arin at the start of the procedure. Use of glycoprotein IIb/IIIa inhibitors
was at the discretion of the PCI operators on the basis of the clinical con-
dition. Creatinine and eGFR were measured on admission and at 24, 48
and 72 h.
2.3. Control group
The Control group consisted of consecutive STEMI patients undergo-
ing PPCI in a previous 6 month period (June 2013 to December 2013).
The same inclusion and exclusion criteria applied. For these patients a
point of care blood test was not performed and the operator was un-
aware of the baseline creatinine and eGFR. PCI procedure and subse-
quent patient's management followed the same standards as the
STATCREAT group.STATCREAT and control groups were further divided into subjects
with chronic kidney disease (CKD) prior to PCI (eGFR b 60 ml/min) or
subjects with normal renal function (eGFR N 60 ml/min). For both
groups the diagnosis of CKD was based on the blood results from the
sample taken immediately prior to PPCI during their index admission:
the point-of-care tested sample for the STACREAT group and the labora-
tory values were made available later for the control group.
2.4. Deﬁnitions
CI-AKI was deﬁned as an absolute increase of serum creatinine ≥
0.5 mg/dl (44 mmol/l) or relative increase ≥25% from baseline value at
72 h post intervention [22]. CKD was deﬁned as eGFR b 60 ml/min per
1.73 m2 pre-PCI [23].
2.5. Study outcomes
Primary endpoints were total volume of contrastmedia used and in-
cidence of CI-AKI. Number of lesions treated and number of stents im-
planted were used to assess impact of pre-procedure renal function
measurements in interventional treatment strategy. Procedure duration
and ﬂuoroscopy time was also documented.
2.6. Statistical analysis
Categorical variables are expressed as percentages and were com-
pared by Fisher's exact test. Continuous variables are presented as
mean with standard deviation. Differences between means have been
tested using a two-sample, two-sided t-test, and the p-values have
been obtained using aMonte Carlo approachwith 10,000 permutations,
using the R package perm. This approach avoids strong distributional
assumptions, such as the normality of data, in the statistical inferences.
A p-value of b0.05 was considered as statistically signiﬁcant. All statisti-
cal analyses have been carried out using the computer program R (R
CRAN 2016).
3. Results
A total of 454 patients were included, 160 in the STATCREAT group
and 294 in the control group. Baseline characteristics for the two co-
horts are shown in Table 1. Mean age was 64 years and 20% of patients
were above 75 years for both groups. In both cohorts the patients were
predominantly male (73.1% vs. 71.2%, p=0.662). There was no statisti-
cally signiﬁcant difference in the presence of major cardiovascular risk
factors. For both groups, the door to balloon timewas 39min. Left ante-
rior descending artery (LAD) was the culprit vessel in 38.4% of patients
in the control group and in 43.1% in the STATCREAT group (p= 0.367).
Both groups had similar numbers of patients with pre-procedure CKD
(19% vs. 21.3%, p= 0.622). The incidence of CI-AKI in the whole popu-
lation of our study was 14.5% and it was not different between the
two groups (14.4% vs. 14.6%, STATCREAT and control groups respective-
ly p = 0.942). For the overall STATCREAT group, contrast dose was
162.2 ml compared to 157.2 ml for the overall control group (p =
0.869).
3.1. Patients with CKD
Results for patientswith pre-procedure CKDare shown in Table 2. 34
(21.2%) patients in the STATCREAT group and 56 (19.0%) in the Control
group were found to have CKD pre-procedure. Contrast media volume
used was reduced in the STATCREAT group by 27.7 ml (124.6 ml vs.
152.3 ml, p= 0.015). The incidence of CI-AKI in the STATCREAT group
was 5.9% (n = 2) compared with 17.9% (n = 10) in the control group
(p= 0.12). Similar numbers of lesions were treated (1.118 vs. 1.196, p
= 0.643) and similar numbers of stents were placed (1.176 vs. 1.250,
p = 0.78) in the two groups. There was no statistically signiﬁcant
Table 1
Baseline patient characteristics.
Control (n= 294) STATCREAT (n= 160) p Value
Age (years) 64 (13) 64 (12) p= 0.83
Age N 75 (%) 59 (20.0) 33 (20.6) p= 0.903
Men (%) 215 (73.1) 114 (71.2) p= 0.662
DM (%) 36 (12.2) 17 (10.6) p= 0.649
HTN (%) 119 (40.5) 53 (33.1) p= 0.13
Hypercholesterolaemia (%) 103 (35.0) 44 (27.5) p= 0.115
Smoker/ex-smoker (%) 165 (56.1) 89 (55.6) p= 0.922
Previous MI (%) 34 (11.6) 18 (11.2) p= 1.0
Previous PCI (%) 28 (9.5) 11 (6.9) p= 0.384
Previous CABG (%) 8 (2.7) 7 (4.4) p= 0.412
LAD infarct (%) 113 (38.4) 67 (43.1) p= 0.367
Baseline serum Cr (mmol/l) 89 ± 35 86 ± 25 p= 0.556
eGFR b 60 (%) 56 (19.0) 34 (21.3) p= 0.622
Hb (g/dl) 14.0 ± 1.8 14.8 ± 11.0 p= 0.161
Values are expressed as means (standard deviation), or percentage.
DM, diabetesmellitus, HTN, hypertension,MI,myocardial infarction, PCI, percutaneous coronary intervention, CABG, coronary artery bypass grafting, LAD, left anterior descending, Cr, cre-
atinine, eGFR, estimate glomerular ﬁltration rate, Hb, haemoglobin.
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or ﬂuoroscopy time (10.27 min vs. 9.87 min, p= 0.779).
3.2. Patients without CKD
For the two groups of patients with normal renal function prior to
the procedure, the volume of contrast media used was numerically
higher for the STATCREAT group (172.4 ml vs. 158.4 ml, p = 0.067),
but this increase did not reach statistical signiﬁcance (Table 3). There
was no statistically signiﬁcant difference in the incidence of CI-AKI
(16.7 vs. 13.4, p= 0.4), the number of lesions treated (1.67 vs. 1.64, p
= 1.0) or the number of stents used (1.214 vs. 1.168, p = 0.611). In
the STATCREAT group, ﬂuoroscopic time was longer by 1.51 min
(10.78 min vs. 9.27 min, p= 0.029). Similarly, the duration of the pro-
cedure was longer for the STATCREAT patients (45.83 min vs.
41.36 min, p= 0.027).
4. Discussion
The present study assessed the impact of point-of-care pre-
procedure creatinine and eGFR measurements in patients with ST seg-
ment elevationmyocardial infarction undergoingprimary PCI in a single
tertiary cardiac centre. The results of thesemeasurementswere instant-
ly available to the operator prior to PCI. Point-of-care testing did not in-
crease door to balloon time. Incidence of CI-AKI in the whole study
cohort was 14.5% and that was not different between the overall
group of patients with pre-PCI renal function testing compared with
the overall control group. Similarly, contrast dose between the two
groups was not different when the total number of patients was com-
pared. In the group of patients who were found to have pre-
procedural CKD, contrast media volume was signiﬁcantly reduced. The
incidence of CI-AKI in this group of patients showed an absolute risk re-
duction by 12%, which was not statistically signiﬁcant. In the group of
patients without pre-procedural CKD, contrast volume and incidenceTable 2
Results in patients with pre-procedure chronic kidney disease (CKD).
STATCREAT 34 patients
Contrast media volume (ml) 124.6 (54.4)
% CI-AKI 5.9%
Number of lesions treated 1.118 (0.41)
Number of stent used 1.176 (0.76)
Procedure duration (minutes) 46.3 (26.4)
Fluoroscopy time (minutes) 10.27 (7.69)
Values are expressed as means ± standard deviations, or percentage.
CI-AKI, contrast-induced acute kidney injury.of CI-AKI were not different, as a numerical increase was not found sta-
tistically signiﬁcant.
CI-AKI has a higher incidence in the STEMI population and leads to
worse prognosis especially in patients with pre-existing chronic kidney
disease [24,25]. A recent study on a large cohort of STEMI patients (n=
2968) showed higher rates of mortality at 30 days (8.0 vs. 0.9%, p =
0.0001) and 3 years (16.2 vs. 4.5%, p= 0.0001) for patients who devel-
opedCI-AKI [4]. Volumeof contrastmedia used is a known risk factor for
the development of CI-AKI [1]. At the emergency setting of primary PCI
there is usually limited information regarding the background of the pa-
tient and most of the times previous blood test results are unavailable.
Our hypothesis was that if the operators performing the PPCI knew
the renal function of the patient, theywould reduce the contrast volume
used in patientswith pre-existing kidney disease and thatwould lead to
a reduced incidence of CI-AKI. Revascularisation is underused in pa-
tients with kidney disease, in view of concerns regarding further deteri-
oration of renal function [26] and we wanted to control for such an
effect. Thus, a speciﬁed endpoint was the comparison between the
number of lesions treated and stents implanted between the two co-
horts. We also documented procedural and ﬂuoroscopic times as safety
endpoints.
We recruited 454 patients with STEMI without cardiogenic shock,
who underwent primary PCI with stent implantation. In our centre me-
chanical circulatory support (MCS) is used only in the context of cardio-
genic shock, so none of the patients in this study received MCS.
Cardiogenic shock by deﬁnition leads to tissue hypoperfusion resulting
to renal injury. Reduction of contrast media volume to the absolute
needed one is important for this group of patients, butwe did not expect
any detectable beneﬁt from our intervention. The incidence of CI-AKI in
the whole population of our study was 14.5%. This was in concordance
with other studies focused in patients with STEMI [3,4], suggesting
that our study population was a representative one.
The negative effect of contrast media in renal function has been
demonstrated in animal models [27] and a clear-cut association of con-
trast media dose with incidence of CI-AKI has been found in patientsControl 56 patients Difference in means p-Value
152.3 (53.3) −27.7 p= 0.015
17.9% p= 0.12
1.196 (0.58) −0.078 p= 0.643
1.246 (0.84) −0.074 p= 0.78
44.4 (19.4) 1.9 p= 0.694
9.87 (5.56) 0.4 p= 0.779
Table 3
Results in patients with no pre-procedure chronic kidney disease (CKD).
STATCREAT Control Difference in means p-Value
Contrast media volume (ml) 172.4 (76.6) 158.4 (66.4) 14 p= 0.067
% CI-AKI 16.7% 13.4% p= 0.4
Number of lesions treated 1.167 (0.518) 1.164 (0.48) 0.003 p= 1.00
Number of stent used 1.214 (0.755) 1.168 (0.715) 0.046 p= 0.611
Procedure duration (minutes) 45.83 (19.57) 41.36 (16.35) 4.47 p= 0.027
Fluoroscopy time (minutes) 10.78 (7.17) 9.27 (5.64) 1.52 p= 0.029
Values are expressed as means (standard deviation), or percentage.
CI-AKI, contrast-induced acute kidney injury.
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volume of contrast media for prevention of CI-AKI is emphasised in cur-
rent percutaneous coronary revascularisation guidelines, especially in
patients with CKD [20,29]. In our study, awareness of pre-existing CKD
disease by operators led to a statistically signiﬁcant reduction of con-
trast by 27.87 ml. This amount is not negligible as a previous study on
patients with CKD undergoing coronary angiography showed that the
risk of CI-AKI doubledwith every 20ml of contrast administered (incre-
mental odds ratio of 2.12, 95% CI 1.4 to 3.4, p=0.0002) [30]. In a meta-
analysis of the effect of automated contrast injection devices on CI-AKI,
an average reduction of 45 ml of contrast per case, led to a reduction of
CI-AKI by 15% [31]. In our study, the mean total volume of contrast
media used in the Control group, where pre-procedure renal function
was unknown, was 152.3ml for patients with CKD and 158.4 ml for pa-
tients without CKD. Both amounts are considerably lower compared
with the 225 to 245 ml used in the subgroup of HORIZONS-AMI and
the 216.1 ml in the study by Sgura et al. [4,24]. This could be the result
of an individual operator's preferences, local protocols or complexity
of cases. For example, in our centre routine ventriculography is not per-
formed, as bedside transthoracic echocardiography is instantly avail-
able. If pre-procedure creatinine and eGFR testing was to be
implemented in centres with higher contrast doses, maybe it would
be space for a largest reduction in contrast volume leading to more pro-
nounced reduction in CI-AKI.
A total volume of contrast media of N350 ml or N4 ml/kg is directly
related to the development of CI-AKI, but the ratio of the volume of con-
trast media to creatinine clearance (CV/CrCl) is a better risk predictor in
individual patients [32,33]. A CV/CrCl N 3.7:1 correlated strongly with
the risk of developing CI-AKI in a mixed population of stable coronary
artery disease and acute myocardial infarction undergoing PCI and pre-
dicted CI-AKI and 1 month mortality in patients undergoing PPCI for
STEMI [34,35]. In the context of STEMI speciﬁcally, an even lower CV/
CrCL ratio of 2.5 has been shown to predict CI-AKI [36]. The above dem-
onstrate the importance of knowing a patient's renal function in ad-
vance before performing the PCI procedure. As shown in our study, by
performing point-of-care instant Cr and eGFRmeasurements, the oper-
ator could guide the intervention accordingly and adjust contrast dose
to the one tolerated by each individual patient based on baseline renal
function.
In the group of patients with pre-existing CKD there was an absolute
risk reduction of 12% (5.9% vs. 17.9%), which did not reach statistical sig-
niﬁcance. This could be explained by the small number of events; with
the cardiogenic shock patients excluded from the analysis, only 2 pa-
tients in the STATCREAT group developed CI-AKI. A larger study is need-
ed to conﬁrm the above ﬁnding.
In patients without CKD, the contrast dose in the STATCREAT group
was increased (absolute mean increase by 14 ml), but this increase was
not statistically signiﬁcant. Equally there was no difference in the inci-
dence of CI-AKI. Given the acute inﬂammation during STEMI and the
high risk of peri-STEMI hemodynamic compromise, a universal “mini-
mize dye” approach should be practiced. A potential false sense of secu-
rity thatwould liberalise contrast usewould be a pitfall for point-of-care
renal function testing in the setting of PPCI. This was not shown in our
study, but it should be tested as a safety endpoint in a larger randomisedtrial. Interestingly, in the non-CKD group of patients, ﬂuoroscopy time
and procedure time were prolonged by 1.51 and 4.47 min respectively.
Importantly, thiswasnot the result ofmore revascularisation as number
of lesions treated and stents used was similar between the two groups.
One particular concern in the study was that the operators might
underuse revascularisation in the group of patients found to have im-
paired renal function pre procedure. The analysis of the data did not
show that effect. The number of the lesions treated and stent used
was similar between the different groups. In any case, knowledge of
pre-procedure renal impairment should not lead to under-utilisation
of clinically needed PCI, but should prompt strategies to reduce contrast
use like use of biplane angiography or intravascular ultrasound to plan
and optimise stent implantation and strategies of renal protection like
hydration.
5. Limitations
The present study has limitations. It is a single centre study and in-
volves a small number of patients who developed CI-AKI. The compari-
son between the groups is not the result of randomisation; a group of
patients recruited prospectively has been compared with a retrospec-
tive historic cohort. We hypothesised that operators were unaware of
the patients' pre-procedure renal function. In the emergency setting of
PPCI, history taking and clinical assessment only take place a few mi-
nutes before the procedure. We cannot exclude that some patients
might have reported pre-existing renal dysfunction or that medical re-
cords were instantly available, introducing an operator bias. Further-
more, operators could have been more careful with contrast usage in
patients who belonged in high-risk groups (i.e. elderly, diabetic) even
without knowing the pre-PCI renal function. Hydration pre, during
and post procedure can prevent CI-AKI [37]. Operators who were
aware of the pre-PPCI renal function apart from reducing the amount
of contrast used, might have been more aggressive with hydration in
patients that could tolerate it. The amount of intravenous ﬂuids given
pre, during and post procedure has not been documented for the pur-
pose of this study. The same applies with the use of potential nephro-
toxic drugs. Their peri-procedural use might have been reduced in the
group of patients with documented pre-PCI CKD. In our study, we
used a speciﬁc point-of-care analyser for renal function testing. There
are multiple devices in the market and the technology itself has limita-
tions compared with standard laboratory testing [38], but this discus-
sion is out of the scope of this paper. The device used in our study has
been tested and proved reliable in other studies [39]. In our centre, for
the ﬁrst 130 patients we compared the point-of-care creatinine results
with the laboratory ones. As shown in Fig. 1, point-of-care results
were adequately accurate. In any case, point-of-care renal function test-
ing in the context of PPCI, does not substitute standard laboratory anal-
ysis, but provides information prior to the procedure that would not be
available otherwise.
6. Conclusions
Pre-PPCI point-of-care measurement of renal function biomarkers
did not reduce the incidence of CI-AKI in the overall group of STEMI
Fig. 1. Scatter plot with passing & Bablok ﬁt for point-of-care and laboratory creatinine measurements.
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have chronic kidney disease pre procedure, contrast media volumewas
signiﬁcantly reduced, but a numerical reduction in the incidence of
acute kidney injury did not reach statistical signiﬁcance. No statistically
signiﬁcant differences were found in the non-CKD group. Larger
randomised trials are needed to investigate further the impact of
point-of-care creatinine and eGFR testing in clinical outcomes for
STEMI patients undergoing PPCI.
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